bundled payments for cardiology, CMS cardiac reimbursements, healthcare reform, July 1 2017

Effective July 1, 2017 for Medicare heart attack patients, the the Centers for Medicare and Medicaid Services (CMS) will move away from its traditional fee-for-service reimbursement to bundled payment models in attempts to reduce healthcare costs. This includes patients with myocardial infarction who undergo percutaneous coronary intervention (PCI) with or without stenting, and coronary bypass graft surgery (CABG). 
  

BioCardia Inc. announced in December the issuance of United States Patent No. 9,517,199 relating to a method of delivering cells to patients who have chronic myocardial infarcts. This new patent follows United States Patent No. 9,504,642, issued to BioCardia two weeks prior.

Whale Imaging Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the G-Arm Duo. The Duo is the next generation of the G-Arm, with major improvements including axial tilt and greater table access.

Lumedx Corp. announced at the end of November that two Marshall Medical Centers hospitals have gone live with the first phase of a cardiovascular information system (CVIS) deployment. The two hospitals now using Lumedx CVIS software are Marshall Medical North in Guntersville, Ala.; and Marshall Medical South in Boaz, Ala.

Arterys has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Arterys Cardio DL application. Arterys Cardio DL is the first technology to be cleared by the FDA that leverages cloud computing and deep learning in a clinical setting.

The FDA confirmed the cybersecurity vulnerabilities of St. Jude ICDs, pacemakes, implantable cardioverter defibrillators, CRT and other EP devices with wireless connections.

January 9, 2017 — The U.S. Food and Drug Administration (FDA) issued a safety communication today concerning patient safety issues due to cybersecurity vulnerabilities found in St. Jude Medical's radio frequency (RF)-enabled implantable cardiac devices and Merlin@home Transmitter. The FDA said it has reviewed information concerning potential cybersecurity vulnerabilities associated with St.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now